Evidence map›Paper›PMID 27800165›Full record

ArticleJournal of pharmaceutical policy and practice2016

Medicine and the future of health: reflecting on the past to forge ahead.

Dale Fisher, Paul Wicks, Zaheer-Ud-Din Babar

Abstract readEditorial
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The future of pharmaceuticals: strategic foresight in an era of uncertainty.Journal of pharmaceutical policy and practice · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Dale FisherInfectious Disease Division, Department of Medicine, National University Hospital; National University Health Systems, 1E Kent Ridge Rd, Singapore, 119228 Singapore ; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Paul WicksPatientsLikeMe, Cambridge, MA USA.
Zaheer-Ud-Din BabarSchool of Pharmacy, University of Auckland, Auckland, New Zealand ; Lahore Pharmacy College, Lahore, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of new therapies has a rich history, evolves quickly with societal trends, and will have an exciting future. The last century has seen an exponential increase in complex interactions between medical practitioners, pharmaceutical companies, governments and patients. We believe technology and societal expectations will open up the opportunity for more individuals to participate as information becomes more freely available and inequality less acceptable. Corporations must recognize that usual market forces do not function ideally in a setting where health is regarded as a human right, and as modern consumers, patients will increasingly take control of their own data, wellbeing, and even the means of production for developing their own treatments. Ethics and legislation will increasingly impact the processes that facilitate drug development, distribution and administration. This article collection is a cross-journal collaboration, between the

Indexed as

AccessAntibioticsCorruptionDrugsDrug shortagesFuturePatient-centred carePharmaceuticalsTechnology

Identifiers

PMID27800165
PMCPMC5078971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.